{
    "clinical_study": {
        "@rank": "137895", 
        "brief_summary": {
            "textblock": "We are interested in studying whether and how medical problems other than primary cancer\n      before hematopoietic cell transplantation would impact the profiles of quality of life and\n      toxicities post-transplantation for patients with blood cancers. We want to see if by\n      assessing comorbidities (such as diabetes) early on, we can identify those patients who will\n      have more toxicities or limitations in their quality of life after transplant. The generated\n      information could set the stage for future intervention studies aiming to improve quality of\n      life for patients with blood cancers after transplantation."
        }, 
        "brief_title": "Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hematologic Malignancies", 
            "Other Diagnoses, Comorbidities, and Complications"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Hematologic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Allogeneic HCT candidates who are >18 years of age\n\n          -  Able to speak and read English\n\n          -  Able to provide informed consent\n\n          -  Access to a telephone for study-related communications\n\n          -  Diagnosed with a hematological malignant disease\n\n          -  Willing to complete survey packets at 5 time-points, spanning two years\n\n        Exclusion Criteria:\n\n          -  HCT candidates who are 18 years or younger at the time of study enrollment\n\n          -  HCT candidates who cannot read, write, or speak English\n\n          -  Patients with diagnoses of non-malignant diseases, or solid tumors are primary\n             disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients diagnosed with hematological malignancies who are being treated with allogeneic\n        hematopoietic cell transplantation (HCT) at the Seattle Cancer Care Alliance."
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930981", 
            "org_study_id": "2574.00", 
            "secondary_id": "4R00HL088021-03"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "quality of life", 
            "toxicities", 
            "hematopoietic stem cell transplantation"
        ], 
        "lastchanged_date": "February 25, 2014", 
        "location": {
            "contact": {
                "email": "erock@fhcrc.org", 
                "last_name": "Emily Rock, MS", 
                "phone": "206-667-2303"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98109"
                }, 
                "name": "Fred Hutchinson Cancer Research Center"
            }, 
            "investigator": {
                "last_name": "Mohamed Sorror, MD, MSc", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prospective Assessment of Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life", 
        "overall_contact": {
            "email": "erock@fhcrc.org", 
            "last_name": "Emily Rock, M.S.", 
            "phone": "206-667-2303"
        }, 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center", 
            "last_name": "Mohamed L Sorror, MD; MSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "A 19-item instrument, it assesses physical symptoms and their interference with life.", 
                "measure": "The MD Anderson Symptom Inventory", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline in Symptoms at 3,6,12,and 24 months"
            }, 
            {
                "description": "A 49-item questionnaire measuring quality of life in bone marrow transplant patients, it measures physical, functional, social/family and emotional well-being in addition to bone marrow transplant-specific concerns.", 
                "measure": "The Functional Assessment of Cancer Therapy Bone Marrow Transplant Scale", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline in Symptoms at 3,6,12,and 24 months"
            }, 
            {
                "description": "This measure is used to measure utilities that can be used to calculate a quality adjusted survival score.", 
                "measure": "The EQ-5D", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline in Symptoms at 3,6,12,and 24 months"
            }, 
            {
                "description": "This measure captures the frequency and diversity of social activities outside of daily responsibilities.", 
                "measure": "The Social Activity Log", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline in Symptoms at 3,6,12,and 24 months"
            }, 
            {
                "description": "This measures social support, including participation in social activities and perception of social support.", 
                "measure": "ENRICHD Social Support Instrument", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline in Symptoms at 3,6,12,and 24 months"
            }, 
            {
                "description": "This is a 25-item scale assessing distress related to perceived demands from events specific to cancer survivors.", 
                "measure": "The Cancer and Treatment Distress Scale", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline in Symptoms at 3,6,12,and 24 months"
            }, 
            {
                "description": "The PHQ-9 measures measures depression and parallels the nine diagnostic symptom criteria of the DSM-IV for Major Depressive Disorder.", 
                "measure": "The Patient Health Questionnaire-9", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline in Symptoms at 3,6,12,and 24 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930981"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "We will measure toxicities using the NCI CTCAE", 
            "measure": "National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE)", 
            "safety_issue": "No", 
            "time_frame": "at 90 days"
        }, 
        "source": "Fred Hutchinson Cancer Research Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Fred Hutchinson Cancer Research Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}